Company description

Groupe SYNERLAB (CDMO) generate a turnover of 130 million euros in 2018 and operate 6 factories in Europe. SYNERLAB currently employ over 1 000  people and are dedicated to pharmaceutical development and manufacturing.Groupe SYNERLAB  offer  solutions for analytical and galenical development, manufacturing and packaging of medicinal products for human, veterinary use, medical devices and food supplements in various dosage forms, especially for solid and liquid oral form, non-injectable sterile liquids and custom freeze-drying. We are one of the leading manufacturers in the markets for pharmaceutical and veterinary products, food supplements, diagnostics and medical devices. As a CDMO specialising in multi-form products, we manufacture all kinds of batches: for clinical trials, pilot batches and industrial batches.Our expertise, combining high demands and safety, is recognised among the leading international laboratories. The combination of our know-how, equipment and production areas provides our customers with an appropriate, flexible response to all their requirements. Our main aim is clearly to provide our customers with relevant responses. Contact : [email protected]

Quick facts

Sales markets Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America
Affiliated categories: Contract Manufacturing |Drug Formulation (general category) |Lyophilisation More

Recently at

5 nov 2019

CPhI Worldwide 2019

5-7 November 2019 Frankfurt, Germany We were at stand 121H21 See our Exhibitor Profile   See full Exhibitor List

Contact information




View all contact information